InvestorsObserver is giving Cardiff Oncology Inc (CRDF) an Analyst Rating Rank of 75, meaning CRDF is ranked higher by analysts than 75% of stocks. The average price target for CRDF is $26.666 and analyst’s rate the stock as a Strong Buy.
Wall Street analysts are rating CRDF a Strong Buy today. Find out what this means to you and get the rest of the rankings on CRDF!
Why are Analyst Ratings Important?
Analysts know the inner workings of the companies they follow better than anyone but the companies’ management. You can learn a lot about a company from studying the financial statements, but analysts ask questions on conference calls and understand the intricacies of each of the businesses they cover. Analysts understand how bad weather in one part of the world can disrupt supply chains, or disrupt shopping patterns. This lets traders make decisions **before** a quarterly report that could be worse than expected.
InvestorsObserver aggregates the ratings of all the analysts covering a given stock, takes the average of those ratings and then percentile ranks the averages. That provides a level of granularity that is significantly better than just the three levels provided by traditional buy/hold/sell ratings.
What's Happening With Cardiff Oncology Inc Stock Today?
Cardiff Oncology Inc (CRDF) stock has gained 6.6% while the S&P 500 is lower by -0.76% as of 12:02 PM on Tuesday, Jul 27. CRDF has risen $0.34 from the previous closing price of $5.15 on volume of 481,885 shares. Over the past year the S&P 500 has gained 35.48% while CRDF has risen 20.13%. CRDF lost -$1.03 per share the over the last 12 months.
Click Here to get the full Stock Report for Cardiff Oncology Inc stock.